Dr Katie Owen
Honorary (Fellow)
The Sir Peter MacCallum Department of Oncology
16 Scholarly works
3 Projects
HIGHLIGHTS
2025
Journal article
Abstract PR-02: Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance
DOI: 10.1158/2326-6074.cimm25-pr-022024
Journal article
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T
DOI: 10.2967/jnumed.124.2676502023
Conference Proceedings
AlphaBet: A Phase I/II trial evaluating the combination of Radium-223 and [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
2023
Conference Proceedings
AlphaBet: A phase I/II trial evaluating the combination of radium-223 and [177Lu]Lu-PSMAI&T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
DOI: 10.1200/jco.2023.41.6_suppl.tps2802022
Research Grant
Development of Preclinical Models of Advanced Prostate Cancer for Radiotherapy and Tumour-Immune Targeting
2022
Research grants (ARC, NHMRC, MRFF)
Boosting Cellular Immunogenicity to Combat Metastatic Cancer
2021
Research Grant
Utilising and Targeting Novel Tumour-Intrinsic Type I Interferon Suppressors to Predict and Prevent Bone Metastasis
RECENT SCHOLARLY WORKS
2022
Journal article
AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
DOI: 10.3389/fmed.2022.10591222022
Journal article
Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer
DOI: 10.1158/2767-9764.CRC-21-01392021
Journal article
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer
DOI: 10.1007/s00262-021-02857-z2020
Book Chapter
Current perspectives on cancer immunotherapy in bone
DOI: 10.1016/b978-0-12-801238-3.11255-32020
Journal article
Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone
DOI: 10.15252/embr.2020501622020
Journal article
Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer
DOI: 10.1002/cti2.1177